Search


VERAXA Biotech, which is part of Switzerland's Xlife Sciences incubator, will be going public in the U.S. via a SPAC in Q4 of this year. The company uses an AND-gating technology for TCEs and ADCs
Xlife Sciences CEO Oliver Baumann introduces us to the fund, which is publicly traded in Switzerland, while VERAXA CEO Christoph Antz...
May 2, 2025






.png)

